Literature DB >> 33386393

Identification of antigens presented by MHC for vaccines against tuberculosis.

Paulo Bettencourt1, Julius Müller2, Annalisa Nicastri3, Daire Cantillon4, Meera Madhavan2, Philip D Charles3, Carine B Fotso2, Rachel Wittenberg2, Naomi Bull2, Nawamin Pinpathomrat2, Simon J Waddell4, Elena Stylianou2, Adrian V S Hill2, Nicola Ternette2,3, Helen McShane2.   

Abstract

Mycobacterium tuberculosis (M.tb) is responsible for more deaths globally than any other pathogen. The only available vaccine, bacillus Calmette-Guérin (BCG), has variable efficacy throughout the world. A more effective vaccine is urgently needed. The immune response against tuberculosis relies, at least in part, on CD4+ T cells. Protective vaccines require the induction of antigen-specific CD4+ T cells via mycobacterial peptides presented by MHC class-II in infected macrophages. In order to identify mycobacterial antigens bound to MHC, we have immunoprecipitated MHC class-I and class-II complexes from THP-1 macrophages infected with BCG, purified MHC class-I and MHC class-II peptides and analysed them by liquid chromatography tandem mass spectrometry. We have successfully identified 94 mycobacterial peptides presented by MHC-II and 43 presented by MHC-I, from 76 and 41 antigens, respectively. These antigens were found to be highly expressed in infected macrophages. Gene ontology analysis suggests most of these antigens are associated with membranes and involved in lipid biosynthesis and transport. The sequences of selected peptides were confirmed by spectral match validation and immunogenicity evaluated by IFN-gamma ELISpot against peripheral blood mononuclear cell from volunteers vaccinated with BCG, M.tb latently infected subjects or patients with tuberculosis disease. Three antigens were expressed in viral vectors, and evaluated as vaccine candidates alone or in combination in a murine aerosol M.tb challenge model. When delivered in combination, the three candidate vaccines conferred significant protection in the lungs and spleen compared with BCG alone, demonstrating proof-of-concept for this unbiased approach to identifying new candidate antigens.

Year:  2020        PMID: 33386393     DOI: 10.1038/s41541-019-0148-y

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN: 2059-0105            Impact factor:   7.344


  57 in total

1.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry.

Authors:  D F Hunt; R A Henderson; J Shabanowitz; K Sakaguchi; H Michel; N Sevilir; A L Cox; E Appella; V H Engelhard
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

2.  Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics.

Authors:  Anthony W Purcell; Sri H Ramarathinam; Nicola Ternette
Journal:  Nat Protoc       Date:  2019-05-15       Impact factor: 13.491

Review 3.  Current approaches toward identifying a correlate of immune protection from tuberculosis.

Authors:  Iman Satti; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2018-12-03       Impact factor: 5.217

4.  Identification by mass spectrometry of CD8(+)-T-cell Mycobacterium tuberculosis epitopes within the Rv0341 gene product.

Authors:  David C Flyer; Venkatesh Ramakrishna; Cara Miller; Helen Myers; Melanie McDaniel; Karen Root; Caroline Flournoy; Victor H Engelhard; David H Canaday; Jarrod A Marto; Mark M Ross; Donald F Hunt; Jeffrey Shabanowitz; Forest M White
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

5.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

Authors:  G A Colditz; T F Brewer; C S Berkey; M E Wilson; E Burdick; H V Fineberg; F Mosteller
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

6.  Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.

Authors:  Venkatesh Ramakrishna; Mark M Ross; Max Petersson; Christine C Gatlin; Charles E Lyons; Cara L Miller; Helen E Myers; Melanie McDaniel; Larry R Karns; Rolf Kiessling; Giorgio Parmiani; David C Flyer
Journal:  Int Immunol       Date:  2003-06       Impact factor: 4.823

7.  MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response.

Authors:  James S Testa; Vivekananda Shetty; Julie Hafner; Zacharie Nickens; Shivali Kamal; Gomathinayagam Sinnathamby; Ramila Philip
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

8.  Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands.

Authors:  Benno Wölk; Claudia Trautwein; Benjamin Büchele; Nadine Kersting; Hubert E Blum; Hans-Georg Rammensee; Andreas Cerny; Stefan Stevanovic; Darius Moradpour; Volker Brass
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

9.  Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells.

Authors:  Nicola Ternette; Hongbing Yang; Thomas Partridge; Anuska Llano; Samandhy Cedeño; Roman Fischer; Philip D Charles; Nadine L Dudek; Beatriz Mothe; Manuel Crespo; William M Fischer; Bette T M Korber; Morten Nielsen; Persephone Borrow; Anthony W Purcell; Christian Brander; Lucy Dorrell; Benedikt M Kessler; Tomáš Hanke
Journal:  Eur J Immunol       Date:  2015-11-04       Impact factor: 5.532

Review 10.  Progress and challenges in TB vaccine development.

Authors:  Gerald Voss; Danilo Casimiro; Olivier Neyrolles; Ann Williams; Stefan H E Kaufmann; Helen McShane; Mark Hatherill; Helen A Fletcher
Journal:  F1000Res       Date:  2018-02-16
View more
  1 in total

1.  Identification of bacteria-derived HLA-bound peptides in melanoma.

Authors:  Shelly Kalaora; Adi Nagler; Deborah Nejman; Michal Alon; Chaya Barbolin; Eilon Barnea; Steven L C Ketelaars; Kuoyuan Cheng; Kevin Vervier; Noam Shental; Yuval Bussi; Ron Rotkopf; Ronen Levy; Gil Benedek; Sophie Trabish; Tali Dadosh; Smadar Levin-Zaidman; Leore T Geller; Kun Wang; Polina Greenberg; Gal Yagel; Aviyah Peri; Garold Fuks; Neerupma Bhardwaj; Alexandre Reuben; Leandro Hermida; Sarah B Johnson; Jessica R Galloway-Peña; William C Shropshire; Chantale Bernatchez; Cara Haymaker; Reetakshi Arora; Lior Roitman; Raya Eilam; Adina Weinberger; Maya Lotan-Pompan; Michal Lotem; Arie Admon; Yishai Levin; Trevor D Lawley; David J Adams; Mitchell P Levesque; Michal J Besser; Jacob Schachter; Ofra Golani; Eran Segal; Naama Geva-Zatorsky; Eytan Ruppin; Pia Kvistborg; Scott N Peterson; Jennifer A Wargo; Ravid Straussman; Yardena Samuels
Journal:  Nature       Date:  2021-03-17       Impact factor: 49.962

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.